The Health Science Lecture Series will present Eva L. Feldman, M.D., Ph.D., director of the A. Alfred Taubman Medical Research Institute at the U-M Medical School and principal investigator of the first FDA-approved trial of a stem cell therapy for ALS, at its fall event on Oct. 2.

She will present details about the Phase 1 findings, and an update on the Phase 2 round of surgeries that is taking place this fall at U-M, during the Health Science Lecture. A question-and-answer session will follow.

The Health Science Lecture Series is sponsored by the Taubman Institute, the Program in Biology and a number of U-M student organizations. The lectures will be held quarterly on the U-M campus and will focus on a wide variety of topics including medical research, public health, bioethics, evolutionary biology, epidemiology and many others.

For more details, visit www.taubmaninstitute.org